297 related articles for article (PubMed ID: 23867252)
1. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
Beebe K; Mollapour M; Scroggins B; Prodromou C; Xu W; Tokita M; Taldone T; Pullen L; Zierer BK; Lee MJ; Trepel J; Buchner J; Bolon D; Chiosis G; Neckers L
Oncotarget; 2013 Jul; 4(7):1065-74. PubMed ID: 23867252
[TBL] [Abstract][Full Text] [Related]
2. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
3. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.
Chan CT; Paulmurugan R; Gheysens OS; Kim J; Chiosis G; Gambhir SS
Cancer Res; 2008 Jan; 68(1):216-26. PubMed ID: 18172314
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
6. Structure of the ATP-binding domain of Plasmodium falciparum Hsp90.
Corbett KD; Berger JM
Proteins; 2010 Oct; 78(13):2738-44. PubMed ID: 20635416
[TBL] [Abstract][Full Text] [Related]
7. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on the microbes that produce heat shock protein 90-targeting antibiotics.
Piper PW; Millson SH
Open Biol; 2012 Dec; 2(12):120138. PubMed ID: 23271830
[TBL] [Abstract][Full Text] [Related]
9. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
10. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells.
Fang S; Fu J; Yuan X; Han C; Shi L; Xin Y; Luo L; Yin Z
Cell Immunol; 2009; 259(1):49-55. PubMed ID: 19560753
[TBL] [Abstract][Full Text] [Related]
12. Systematic identification of the HSP90 candidate regulated proteome.
Wu Z; Gholami AM; Kuster B
Mol Cell Proteomics; 2012 Jun; 11(6):M111.016675. PubMed ID: 22337586
[TBL] [Abstract][Full Text] [Related]
13. First Structural View of a Peptide Interacting with the Nucleotide Binding Domain of Heat Shock Protein 90.
Raman S; Singh M; Tatu U; Suguna K
Sci Rep; 2015 Nov; 5():17015. PubMed ID: 26599366
[TBL] [Abstract][Full Text] [Related]
14. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
Wang Y; Koay YC; McAlpine SR
Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
[TBL] [Abstract][Full Text] [Related]
15. Structure-based and in silico design of Hsp90 inhibitors.
Sgobba M; Rastelli G
ChemMedChem; 2009 Sep; 4(9):1399-409. PubMed ID: 19685544
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
17. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90: inhibitors in clinical trials.
Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
[No Abstract] [Full Text] [Related]
19. Features of the Streptomyces hygroscopicus HtpG reveal how partial geldanamycin resistance can arise with mutation to the ATP binding pocket of a eukaryotic Hsp90.
Millson SH; Chua CS; Roe SM; Polier S; Solovieva S; Pearl LH; Sim TS; Prodromou C; Piper PW
FASEB J; 2011 Nov; 25(11):3828-37. PubMed ID: 21778327
[TBL] [Abstract][Full Text] [Related]
20. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.
Zhang MQ; Gaisser S; Nur-E-Alam M; Sheehan LS; Vousden WA; Gaitatzis N; Peck G; Coates NJ; Moss SJ; Radzom M; Foster TA; Sheridan RM; Gregory MA; Roe SM; Prodromou C; Pearl L; Boyd SM; Wilkinson B; Martin CJ
J Med Chem; 2008 Sep; 51(18):5494-7. PubMed ID: 18800759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
